Pfizer and BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization in Individuals Aged ≥12 Years
Shots:
- Health Canada has granted authorization for Comirnaty original & Omicron BA.4/BA.5 as a 30μg booster dose in individuals aged ≥12yrs. to provide broader immunization against COVID-19. The companies will submit an application to Health Canada for review of a bivalent vaccine in children aged 5-11yrs.
- The authorization was based on clinical, pre-clinical & manufacturing data for Omicron BA.4/BA.5-adapted bivalent vaccine & monovalent (original vaccine) data. In individuals aged ≥12yrs., a clinical study of bivalent vaccine is now conducted to assess its safety, tolerability, & immunogenicity
- Comirnaty original & Omicron BA.4/BA.5 combines 15μg of mRNA encoding spike protein of wild-type of SARS-CoV-2 & 15μg for Omicron BA.4/BA.5 subvariants
Ref: BioNTech | Image: BioNTech
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
